Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ibio ( (IBIO) ) has provided an update.
On November 20, 2025, iBio, Inc. held its Annual Meeting of Stockholders where four proposals were voted on. The election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, was confirmed for a three-year term. Stockholders ratified Grassi & Co. as the independent auditor for the fiscal year ending June 30, 2026. Additionally, stockholders approved executive compensation on an advisory basis and decided on a one-year frequency for future advisory votes on executive compensation, aligning with the Board’s recommendation.
The most recent analyst rating on (IBIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.
Spark’s Take on IBIO Stock
According to Spark, TipRanks’ AI Analyst, IBIO is a Underperform.
Ibio’s overall stock score is primarily impacted by its poor financial performance and challenging valuation. Technical analysis indicates bearish momentum, further weighing on the score. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IBIO stock, click here.
More about Ibio
Average Trading Volume: 3,475,007
Technical Sentiment Signal: Sell
Current Market Cap: $24.51M
Learn more about IBIO stock on TipRanks’ Stock Analysis page.